Fast Five Quiz: Idiopathic Pulmonary Fibrosis Differential Diagnosis

Guy W. Soo Hoo, MD, MPH; Zab Mosenifar, MD

January 26, 2023

The 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines recommend two antifibrotic agents for the treatment of IPF: nintedanib and pirfenidone. Although neither is curative, studies have demonstrated that both can slow the fibrotic changes associated with IPF, which preserves lung function and reduces the risk for acute exacerbations.

Radiation and chemotherapy are typically not recommended for the management of IPF.

Support groups may be helpful for patients with IPF, but this is not a reason for the importance of establishing an early diagnosis.

Learn more about antifibrotic agents for IPF.

Editor's Recommendations

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Guy W. Soo Hoo, Zab Mosenifar. Fast Five Quiz: Idiopathic Pulmonary Fibrosis Differential Diagnosis - Medscape - Jan 26, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.